House Bill 37 amends various sections of the Tennessee Code Annotated to enhance the use of non-opioid treatments for pain management within group insurance plans. The bill introduces a new part under Title 56, Chapter 7, which defines key terms such as "group insurance plan," "healthcare prescriber," "insurer," and "non-opioid treatment." It mandates that insurers must not disadvantage or discourage the coverage of non-opioid drugs approved by the FDA for pain management compared to opioid medications. This provision applies immediately upon FDA approval of a non-opioid drug, regardless of its review status by the insurer.

Additionally, the bill requires insurers to ensure reimbursement for healthcare prescribers who provide non-opioid treatments to covered employees and mandates separate reimbursement for hospitals offering non-opioid treatments as part of inpatient or outpatient services. The act is set to take effect on July 1, 2025, emphasizing the importance of promoting non-opioid alternatives in pain management to address the ongoing opioid crisis.